Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.

@article{Jauregui2005RandomizedDC,
  title={Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.},
  author={Luis E. Jauregui and Simon Babazadeh and Elyse Seltzer and Lisa D. Goldberg and Dainis Krieviņ{\vs} and Mark Frederick and David A. Krause and Igors Satilovs and Zilvinas Endzinas and Jeffrey G Breaux and William D. O'Riordan},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2005},
  volume={41 10},
  pages={1407-15}
}
BACKGROUND Dalbavancin, a novel lipoglycopeptide with a pharmacokinetic profile that allows weekly dosing, is active against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The efficacy of dalbavancin for treatment of skin and skin structure infections (SSSIs) was demonstrated in a phase 2 study. METHODS In a phase 3 noninferiority study, patients with complicated SSSIs, including infections known or suspected to involve MRSA, were randomized (ratio, 2… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 75 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Similar Papers

Loading similar papers…